Source: Annual Congress 2007 - Epidemiology of tuberculosis II
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. Saka, M. Aydogdu, F. Cimen, H. Calisir, M. Ogretensoy (Ankara, Istanbul, Turkey). Relapse and failure pulmonary tuberculosis patients have the chance of cure with major antituberculosis drugs. Eur Respir J 2007; 30: Suppl. 51, 3825

Member's Comments

No comment yet.

Related content which might interest you: Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001 Evaluation of relapse and defaulter pulmonary tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 647s Year: 2005 Reevaluation of treatment outcome of relapse and defaulter pulmonary tuberculosis cases Source: Eur Respir J 2004; 24: Suppl. 48, 650s Year: 2004 Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB Source: Eur Respir J 2006; 28: Suppl. 50, 8s Year: 2006 Side-effect in the treatment of pulmonary tuberculosis by first-line drugs Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009 Predictors of treatment failure among pulmonary tuberculosis patients in Pakistan Source: International Congress 2019 – Tuberculosis: from diagnosis to complications Year: 2019 Diaskintest at patients after successful treatment of lung tuberculosis Source: International Congress 2017 – Migrants and screening Year: 2017 Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 The evaluation of the relapse or treatment interrupted pulmonary tuberculosis cases Source: Eur Respir J 2006; 28: Suppl. 50, 21s Year: 2006 Side effects of antituberculosis drugs in treatment of patients with newly detected pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 197s Year: 2007 Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis? Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008 Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Recurrence after successful treatment among patients with multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Statin with standard antituberculosis regimen and mortality in hospitalized pulmonary tuberculosis Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Prevalence of MDR and XDR tuberculosis among patients with failure of re-treatment course Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Treatment results in patients with drug resistant pulmonary tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 612s Year: 2002 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Chemotherapy efficacy in TB patients resistant to major and reserve drugs Source: Eur Respir J 2005; 26: Suppl. 49, 648s Year: 2005